Rivaroxaban Patent Expiration
Rivaroxaban is Used for reducing the risk of clot-related complications in various cardiovascular conditions, including deep vein thrombosis and pulmonary embolism in pediatric and adult patients. It was first introduced by Janssen Pharmaceuticals Inc
Rivaroxaban Patents
Given below is the list of patents protecting Rivaroxaban, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xarelto |
US10828310 (Pediatric) | Reducing the risk of cardiovascular events | Jul 31, 2039 | Janssen Pharms |
| Xarelto | US10828310 | Reducing the risk of cardiovascular events | Jan 31, 2039 | Janssen Pharms |
| Xarelto |
US9539218 (Pediatric) | Prevention and treatment of thromboembolic disorders | Aug 17, 2034 | Janssen Pharms |
| Xarelto | US9539218 | Prevention and treatment of thromboembolic disorders | Feb 17, 2034 | Janssen Pharms |
| Xarelto |
US9415053 (Pediatric) | Solid, orally administrable pharmaceutical composition | May 13, 2025 | Janssen Pharms |
| Xarelto |
US7157456 (Pediatric) | Substituted oxazolidinones and their use in the field of blood coagulation | Feb 28, 2025 | Janssen Pharms |
| Xarelto | US9415053 | Solid, orally administrable pharmaceutical composition | Nov 13, 2024 | Janssen Pharms |
| Xarelto | US7157456 | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug 28, 2024
(Expired) | Janssen Pharms |
| Xarelto | US7585860 | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec 11, 2020
(Expired) | Janssen Pharms |
| Xarelto | US7585860 | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec 11, 2020
(Expired) | Janssen Pharms |
| Xarelto | US7592339 | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec 11, 2020
(Expired) | Janssen Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Rivaroxaban's patents.
Latest Legal Activities on Rivaroxaban's Patents
Given below is the list recent legal activities going on the following patents of Rivaroxaban.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Jun, 2024 | US9539218 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Apr, 2024 | US10828310 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Jan, 2024 | US9415053 |
| Termination or Final Written Decision | 28 Jul, 2023 | US10828310 |
| Request for Trial Granted Critical | 19 Oct, 2022 | US10828310 |
| Petition Requesting Trial | 30 Sep, 2022 | US10828310 |
| Petition Requesting Trial | 27 Sep, 2022 | US10828310 |
| Petition Requesting Trial | 09 Sep, 2022 | US10828310 |
| Petition Requesting Trial | 08 Sep, 2022 | US10828310 |
| Request for Trial Granted Critical | 09 Aug, 2022 | US10828310 |
Rivaroxaban's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Rivaroxaban:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Rivaroxaban has 1 clinical trial that has been verified in 2024.